Warning Letter — Gopaldas Visram & Co., Ltd.
The FDA issued a Warning Letter to Gopaldas Visram & Co., Ltd. on June 2, 2026, following a review by the Center for Drug Evaluation and Research (CDER).
This notice affects Gopaldas Visram & Co., Ltd., as well as quality and regulatory departments overseeing drug manufacturing compliance at this facility.
The issuance of a Warning Letter by CDER indicates documented deviations from current good manufacturing practice (CGMP) standards. While the specific nature of the violations is not detailed in the provided excerpt, such letters typically signify significant regulatory risk that could lead to import alerts or restricted product distribution if deficiencies are not remediated.
Regulatory and QA teams should review current manufacturing and quality controls to ensure alignment with CGMP standards. Companies may consider performing an internal audit of the cited facility's compliance status if it is part of their supply chain.
FDA Warning Letter issued to: Gopaldas Visram & Co., Ltd.. 06/02/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gopaldas-visram-co-ltd-721755-06022026
Open in openFDA / FDA.gov